))
Episode 25. Managing Acute Toxicities of CAR T-cell Therapy
Manage episode 367350833 series 3369804
Innhold levert av Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center.
Here are some of the key articles we discussed:
1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”.
https://pubmed.ncbi.nlm.nih.gov/36989488/
2. CAR-HEMATOTOX score:
https://pubmed.ncbi.nlm.nih.gov/34166502/
3. “How I treat cytopenias after CAR T-cell therapy”.
https://pubmed.ncbi.nlm.nih.gov/36800563/
4. Immune Effector Cell-Associated HLH-Like Syndrome (ASTCT):
https://pubmed.ncbi.nlm.nih.gov/36906275/
5. ASTCT consensus grading for CRS and ICANS:
https://pubmed.ncbi.nlm.nih.gov/30592986/
6. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy:
https://pubmed.ncbi.nlm.nih.gov/35696759/
7. Modified EASIX score for predicting CRS and neurotoxicity:
47 episoder
Del
